Vaidyanathan, S;
Kerschner, JL;
Paranjapye, A;
Sinha, V;
Lin, B;
Bedrosian, TA;
Thrasher, AJ;
... Porteus, MH; + view all
(2024)
Investigating adverse genomic and regulatory changes caused by replacement of the full-length CFTR cDNA using Cas9 and AAV.
Molecular Therapy Nucleic Acids
, 35
(1)
, Article 102134. 10.1016/j.omtn.2024.102134.
Preview |
PDF
1-s2.0-S2162253124000210-main.pdf - Published Version Download (3MB) | Preview |
Abstract
A “universal strategy” replacing the full-length CFTR cDNA may treat >99% of people with cystic fibrosis (pwCF), regardless of their specific mutations. Cas9-based gene editing was used to insert the CFTR cDNA and a truncated CD19 (tCD19) enrichment tag at the CFTR locus in airway basal stem cells. This strategy restores CFTR function to non-CF levels. Here, we investigate the safety of this approach by assessing genomic and regulatory changes after CFTR cDNA insertion. Safety was first assessed by quantifying genetic rearrangements using CAST-seq. After validating restored CFTR function in edited and enriched airway cells, the CFTR locus open chromatin profile was characterized using ATAC-seq. The regenerative potential and differential gene expression in edited cells was assessed using scRNA-seq. CAST-seq revealed a translocation in ∼0.01% of alleles primarily occurring at a nononcogenic off-target site and large indels in 1% of alleles. The open chromatin profile of differentiated airway epithelial cells showed no appreciable changes, except in the region corresponding to the CFTR cDNA and tCD19 cassette, indicating no detectable changes in gene regulation. Edited stem cells produced the same types of airway cells as controls with minimal alternations in gene expression. Overall, the universal strategy showed minor undesirable genomic changes.
| Type: | Article |
|---|---|
| Title: | Investigating adverse genomic and regulatory changes caused by replacement of the full-length CFTR cDNA using Cas9 and AAV |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.omtn.2024.102134 |
| Publisher version: | http://dx.doi.org/10.1016/j.omtn.2024.102134 |
| Language: | English |
| Additional information: | © 2024 The Author(s). Published by Elsevier under a Creative Commons license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | CFTR gene regulation, CFTR genome editing, CFTR super-exon, MT: RNA/DNA Editing, airway basal cell differentiation, airway stem cell therapy, cystic fibrosis, genetic rearrangements, universal CFTR correction |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10188561 |
Archive Staff Only
 |
View Item |
